Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Aurelia Lamanuzzi 1, * , Ilaria Saltarella 1, * , Vanessa Desantis 1 , Maria Antonia Frassanito 2 , Patrizia Leone 1 , Vito Racanelli 1 , Beatrice Nico 3 , Domenico Ribatti 3, 4 , Paolo Ditonno 5 , Marcella Prete 1 , Antonio Giovanni Solimando 1 , Francesco Dammacco 1 , Angelo Vacca 1 and Roberto Ria 1 1 Department of Biomedical Sciences and Human Oncology, Internal Medicine Unit G. Baccelli, University of Bari Aldo Moro Medical School, Bari, Italy 2 Department of Biomedical Sciences and Human Oncology, General Pathology Unit, University of Bari Aldo Moro Medical School, Bari, Italy 3 Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, Section of Human Anatomy and Histology, University of Bari Aldo Moro Medical School, Bari, Italy 4 National Cancer Institute Giovanni Paolo II, Bari, Italy 5 Hematology Unit, Di Venere Hospital, Bari, Italy * These authors have contributed equally to this work Correspondence to: Angelo Vacca, email: angelo.vacca@uniba.it Keywords: angiogenesis; endothelial cells; multiple myeloma; mTOR; PP242 Received: June 08, 2017 Accepted: March 13, 2018 Published: April 17, 2018 ABSTRACT The mammalian Target of Rapamycin (mTOR) is an intracellular serine/threonine kinase that mediates intracellular metabolism, cell survival and actin rearrangement. mTOR is made of two independent complexes, mTORC1 and mTORC2, activated by the scaffold proteins RAPTOR and RICTOR, respectively. The activation of mTORC1 triggers protein synthesis and autophagy inhibition, while mTORC2 activation promotes progression, survival, actin reorganization, and drug resistance through AKT hyper-phosphorylation on Ser473. Due to the mTOR pivotal role in the survival of tumor cells, we evaluated its activation in endothelial cells (ECs) from 20 patients with monoclonal gammopathy of undetermined significance (MGUS) and 47 patients with multiple myeloma (MM), and its involvement in angiogenesis. MM-ECs showed a significantly higher expression of mTOR and RICTOR than MGUS-ECs. These data were supported by the higher activation of mTORC2 downstream effectors, suggesting a major role of mTORC2 in the angiogenic switch to MM. Specific inhibition of mTOR activity through siRNA targeting RICTOR and dual mTOR inhibitor PP242 reduced the MM-ECs angiogenic functions, including cell migration, chemotaxis, adhesion, invasion, in vitro angiogenesis on Matrigel ® , and cytoskeleton reorganization. In addition, PP242 treatment showed anti-angiogenic effects in vivo in the Chick Chorioallantoic Membrane (CAM) and Matrigel ® plug assays. PP242 exhibited a synergistic effect with lenalidomide and bortezomib, suggesting that mTOR inhibition can enhance the anti-angiogenic effect of these drugs. Data to be shown indicate that mTORC2 is involved in MM angiogenesis, and suggest that the dual mTOR inhibitor PP242 may be useful for the anti-angiogenic management of MM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Lobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209
Lee, H.-P., Lin, C.-Y., Shih, J.-S., Fong, Y.-C., Wang, S.-W., Li, T.-M., & Tang, C.-H. (2015) · Oncotarget · doi:10.18632/oncotarget.5479 · Cited by 94
Cited by
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Saltarella, I., Desantis, V., Melaccio, A., Solimando, A. G., Lamanuzzi, A., Ria, R., Storlazzi, C. T., Mariggiò, M. A., Vacca, A., & Frassanito, M. A. (2020) · Cells · doi:10.3390/cells9010167 · Cited by 127
Self-citationDrug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
Self-citationKamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
“Extrinsic mechanisms take place in the BM niche, where endothelial cells, fibroblasts, osteoblasts, osteoclasts, and immune cells are closely connected to each other as well as the TME [234].”
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062919 · Cited by 11
“Given that the inhibition of mTORC2 has the synergistic anti-MM effects with a proteasome inhibitor and IMiD [51,52], the dual blockade of RSK2 and AKT may be expected to enhance the effects of proteasome inhibitors and IMiDs on myeloma cells.”
BackgroundInfluential
Metadata
- Authors
- Lamanuzzi, A., Saltarella, I., Desantis, V., Frassanito, M. A., Leone, P., Racanelli, V., Nico, B., Ribatti, D., Ditonno, P., Prete, M., Solimando, A. G., Dammacco, F., Vacca, A., & Ria, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-04-17
- Volume
- 9
- Issue
- 29
- Pages
- 20563-20577
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2801437776
- Cited by
- 60
- References
- 5
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. https://app.cochat.ai/papers/10.18632/oncotarget.25003
- The paper
- Lamanuzzi, A., Saltarella, I., Desantis, V., Frassanito, M. A., Leone, P., Racanelli, V., Nico, B., Ribatti, D., Ditonno, P., Prete, M., Solimando, A. G., Dammacco, F., Vacca, A., & Ria, R. (2018). Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget. https://doi.org/10.18632/oncotarget.25003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.